Immupharma Share News (IMM)
IMM Share
IMM Share
IMM Share
IMM Share
IMM
IMM Share
IMM Level 2
IMM Live
IMM Broker
IMM Directors
IMM Financial
IMM
IMM Short
IMM
Last checked at -
Drug development firm ImmuPharma said Monday that its key scientific collaboration partner and the inventor of ImmuPharma's lead compound, Lupuzor, has confirmed the effectiveness of a product known as Lupuzor peptide P140. Partner CNRS released a statement saying that in a clinical trial involvin
Read moreDrug development firm ImmuPharma increased its losses during 2011 but managed to regain the rights to its most important compound. The loss for the year was £3.35m, against the prior year's loss of £1.98m. The loss per share increased from 2.44p in 2010 to 4.12p in 2011. ImmuPharma's lead product
Read moreThe Managing Director of SABMiller's African division bought a round of shares just one day before the drinks giant announced it has signed a definitive transaction agreement with Anadolu Group and Anadolu Efes. The agreement allows the firm to form a strategic alliance between the firm's divisions
Read moreDrug discovery group Immupharma fell into losses in the year to 31 December, but pointed to progress with its ongoing trials. Pre-tax losses totalled £2m for the year, against a profit of £9.1m the previous year. Revenues fell to just £325,000 from £22.05m. "Early results of our cancer programme
Read moreDow Jones smallcap news is on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps MARIANA RESOURCES LTD. (MARL.LN), a gold, silver and copper explorer, Wednesday said it agreed to raise GBP6.75 million in a share sale to fund drilling at i
Read moreLONDON (Dow Jones)--Immupharma PLC (IMM.LN), a specialist drug discovery and development company, said Wednesday that Cephalon Inc. (CEPH), its license partner for IPP-201101 (Rigerimod; Lupuzor) has started the recruitment of lupus patients for a Phase IIb trial in the U.S. MAIN FACTS: -Stu
Read moreEngineering consultant White Young Green has traded in line with expectations since the end of June, with conditions varying across its markets. "There remains a lack of confidence and liquidity in many areas in which we trade, but there are also some encouraging signs in respect of opportunities
Read more
Last checked at